The stock of CERo Therapeutics Holdings Inc. (CERO) has seen a 19.35% increase in the past week, with a -16.66% drop in the past month, and a -83.07% decrease in the past quarter. The volatility ratio for the week is 20.86%, and the volatility levels for the past 30 days are at 18.82% for CERO. The simple moving average for the past 20 days is 5.55% for CERO’s stock, with a -95.67% simple moving average for the past 200 days.
Is It Worth Investing in CERo Therapeutics Holdings Inc. (NASDAQ: CERO) Right Now?
The 36-month beta value for CERO is also noteworthy at -0.37.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CERO is 9.65M, and at present, short sellers hold a 13.34% of that float. The average trading volume of CERO on July 26, 2024 was 3.96M shares.
CERO) stock’s latest price update
The stock price of CERo Therapeutics Holdings Inc. (NASDAQ: CERO) has dropped by -1.04 compared to previous close of 0.24. Despite this, the company has seen a gain of 19.35% in its stock price over the last five trading days. globenewswire.com reported 2024-06-13 that Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236.
CERO Trading at -56.19% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.14% of loss for the given period.
Volatility was left at 18.82%, however, over the last 30 days, the volatility rate increased by 20.86%, as shares sank -22.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -79.22% lower at present.
During the last 5 trading sessions, CERO rose by +18.00%, which changed the moving average for the period of 200-days by -97.81% in comparison to the 20-day moving average, which settled at $0.2227. In addition, CERo Therapeutics Holdings Inc. saw -97.83% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CERO
Equity return is now at value -1708.01, with -33.39 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.47.
Conclusion
In summary, CERo Therapeutics Holdings Inc. (CERO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
